Faculty : Faculty

Mingjiang Xu, MD, PhD

Associate Professor of Biochemistry and Molecular Biology
Primary Appointment of Biochemistry and Molecular Biology
(305) 243-7831
Gautier Building Room #411
Research Area: Molecular Mechanisms Involved in Genetic Disease and Cancer.
Lab Website: DrXuLab.com
Publications: PubMed

Publication In press:

The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Zhao Z, Chen S, Zhu X, Pan F, Li R, Zhou Y, Yuan W, Ni H, Yang F-C, Xu M. Leukemia 2016 In press.

Research Interests:

  • Roles of TET2 and PHF6 mutations in the pathogenesis of hematological malignancies
  • Roles of long noncoding RNAs in the pathogenesis of myeloid malignancies
  • Roles of TET1 in the pathogenesis of hematological malignancies
  • Development of novel therapeutics for hematological malignancies


  • 2001 PhD University of Tokyo, Tokyo, Japan
  • 1994 MD Shandong University School of Medicine, Jinan, China


Dr. Xu is a well establish scientist in the field of epigenetics and hematological malignancies. Dr. Xu has been investigating the cellular, epigenetic and molecular mechanisms underlying the pathogenesis of hematological malignancies by focusing on several patient-derived gene mutations implicated in epigenetic regulation and dys-regulated long noncoding RNAs. His ultimate goal is to identify novel therapeutic targets/strategies and to develop effective therapies for hematological malignancies. He has authored over 70 peer-reviewed papers in this field of research.

Dr. Xu started his independent career as an Assistant Professor at Mount Sinai School of Medicine, New York, then as an Associate Professor at Indiana University School of Medicine, Indianapolis. In March 2015, he moved to University of Miami Miller School of Medicine as an Associate Professor in the Department of Biochemistry & Molecular Biology and Sylvester Comprehensive Cancer Center.

Dr. Xu is a member of several professional societies and serves on the review boards for a number of professional journals and funding agencies.